Samuel Rabkin
Professor of Neurosciences Harvard Medical School
Seminars
Wednesday 28th January 2026
Integrating Oncolytic Viruses with DDR Inhibitors to Drive Progress in Glioblastoma Therapy
3:45 pm
• Highlighting oncolytic herpes simplex virus (oHSV) combinations with DDR inhibitors that synergize in treating glioblastoma
• Using patient-derived human and mouse glioblastoma stem-like cells (GSCs) as representative preclinical models to assess therapy
• Targeting cancer stem cells with DNA-PK inhibitors and oHSV
